Treatment For Maple Syrup Urine Disease Among 10 New EU Filings

REC 0545, for MSUD, and aztreonam-avibactam, for serious Gram-negative bacterial infections, are among the latest drugs that the European Medicines Agency has started reviewing for potential pan-EU marketing approval.

The EU regulator has started reviewing marketing applications for a new batch of medicines • Source: Shutterstock

REC 0545, Recordati’s investigational treatment for maple syrup urine disease (MSUD), a rare genetic metabolic disorder that starts in early infancy, is among the latest products that the European Medicines Agency has begun reviewing for potential pan-EU marketing authorization.

MSUD, which gets its name from the distinctive sweet odor of urine in infants with the condition, is a disease...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards